Who Will Win This Small Drug Market?

Isis (NASDAQ: ISIS  ) and Sanofi (NYSE: SNY  ) received Food and Drug Administration approval this week for homozygous familial hypercholesterolemia (HoFH) treatment Kynamro. HoFH is a rare genetic disease that causes severely high LDL levels that pose cardiac risks. The patient pool resembles a puddle and already contains a contender: Aegerion's (NASDAQ: AEGR  )  Juxtapid received approval last month.

Who will win?

Close match
HoFH treatments qualify for orphan status, which means that the patient population is small but the drugs can carry a higher price tag to compensate. The battle between Kynamro and Juxtapid might never have a clear victor, though I'd personally consider Juxtapid the stronger candidate.

Juxtapid and Kynamro have run nearly parallel down the pipelines, and both have proven effective while also presenting comparable liver safety risks. But Kynamro had an additional health risk that raised questions last fall.

When Juxtapid went before an FDA panel, the vote was 13-2 in favor of approval. Kynamro's panel voted 9-6 the following day, citing concerns with the abnormal tissue growth that appeared in 3.1% of the trial's patients. Kynamro later received a negative recommendation from the European Medicines Agency, which disagreed with the FDA that the merits outweighed the cancer risks.

But both drugs might find a market. HoFH treatment often requires patients to try different drugs until striking upon the right combination. Kynamro seems at a disadvantage due to the safety issue, but Isis also has Sanofi in its corner.

Juxtapid is Aegerion's only drug, putting it in a particularly vulnerable position. The company announced a last-minute deal with its development partner Catalant, but that's not in the same league as Sanofi. A vague secondary offering was announced early this month to help fund Juxtapid's launch.

Another step back
Juxtapid could best Kynamro financially if Aegerion received an indication expansion to include heterozygous familial hypercholesterolemia (heFH) – the far more common genetic cholesterol condition. Juxtapid and Kynamro might face expansion difficulties due to their liver safety risks, but if one makes it through, it will probably be Juxtapid.

That market won't be an easy win either as it might become crowded with a new group of statin rivals running up the pipes. Statins like Pfizer (NYSE: PFE  ) 's off-patent Lipitor tend to lack the strength required to manage the severely high LDL levels associated with heFH or HoFH. While the companies pushing the potent new drugs openly pursue general high-cholesterol patients, these rare genetic conditions would make for an easier sell.

Foolish final thoughts
Juxtapid will likely sell well within its market. But the key question remains: What will Aegerion do next? Until the answer to that question becomes clear, I'm going to play the waiting game.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 31, 2013, at 3:08 PM, duffer5048 wrote:

    The reason the statins are not effective in HoFH or severe hypercholesterolemia of HeFH is that the genetic defect in the patients prevents the binding and/or internalization of LDL by the LDL receptors on the liver. As a result, the statins, which primarily work by increasing the expression of the LDL receptor, have limited or no benefit in these patients. The PCSK9 inhibitors being developed by a number of companies (Regeneron/Sanofi, Amgen, Pfizer, Roche, etc.) prevent the degradation of the LDL receptor by this particular enzyme (PCSK9). If successful, they will improve the potency of the statins, but will still have no effect in HoFH and some HeFH patients. At this time, Juxtapid and Kynamro are their only pharmaceutical options.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2227456, ~/Articles/ArticleHandler.aspx, 12/21/2014 7:13:39 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement